In addition to 3,4,6-O-Bu3ManNAc, the tributanoylated GlcNAc analog (3,4,6-O-Bu3GlcNAc) downregulated the NF-κB activity in those cancer studies too [116], which was reminiscent of the therapeutic effect of GlcNAc analogs in OA. The gene discussed is NFKB1; the disease is cancer.